PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
Ghaneya Al‐Khadairi(Hamad bin Khalifa University), Julie Decock(Hamad bin Khalifa University)
Cited by 66
Related Papers
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
|Frontiers in Immunology|2018|400
Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
|Journal of Cellular and Molecular Medicine|2021|34
Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
|Cancer Immunology Immunotherapy|2020|31
Cancer testis antigens: Emerging therapeutic targets leveraging genomic instability in cancer
|Molecular Therapy Oncology|2024|19